ライフサイエンスコーパス: multiorgan failure

1 nvestigator (pneumonia, and septic shock and multiorgan failure).

2 chemotherapy died of toxicity (infectious or multiorgan failure).

3 on, and those with burn-associated sepsis or multiorgan failure.

4 D with subsequent respiratory compromise and multiorgan failure.

5 atic disorder leading to heart, and possibly multiorgan failure.

6 opposed, may result in tissue damage or even multiorgan failure.

7 ts/microL and albuminemia <35 g/L) died from multiorgan failure.

8 to a rapidly fatal meningoencephalitis with multiorgan failure.

9 t who had a combination of syndromes died of multiorgan failure.

10 own origin, complicated by septic shock with multiorgan failure.

11 mortality among critically ill patients with multiorgan failure.

12 AMI VSR is advisable before establishment of multiorgan failure.

13 he patient with single LuTX died from septic multiorgan failure.

14 8 months, with 7 deaths caused by cardiac or multiorgan failure.

15 nt-related death secondary to sepsis-induced multiorgan failure.

16 nd could be responsible for septic shock and multiorgan failure.

17 tant clinical outcomes, such as mortality or multiorgan failure.

18 ignancy, and severe cutaneous reactions with multiorgan failure.

19 iated with infection, hepatotoxicity, and/or multiorgan failure.

20 to a sudden loss of hepatic cells leading to multiorgan failure.

21 reas leading causes of death were sepsis and multiorgan failure.

22 th included sepsis, right heart failure, and multiorgan failure.

23 ly but died in the postoperative period from multiorgan failure.

24 y ET and suggest that it causes death due to multiorgan failure.

25 scular complications that ultimately promote multiorgan failure.

26 thrombocytopenia, Aspergillus infection, and multiorgan failure.

27 Of these seven deaths, all were related to multiorgan failure.

28 ly four (12%) of these patients died, all of multiorgan failure.

29 underwent liver-lung transplant, one died of multiorgan failure 11 days after transplant compared wit

30 longed aplasia (1), fungal pneumonia (1), or multiorgan failure (2).

31 The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and

32 was associated with increased postoperative multiorgan failure [42 (35%) vs 56 (20.4%), P = 0.001] a

33 One patient died of multiorgan failure 5 months after transplantation.

34 d death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO p

35 fections characterized by rash, hypotension, multiorgan failure and a high mortality rate.

36 e of UGIB in patients under AT are degree of multiorgan failure and comorbidity, but not AT itself.

37 syndrome (SIRS) and the events that lead to multiorgan failure and death are poorly understood.

38 usion that AG 556 prevented cytokine-induced multiorgan failure and death during septic shock by inhi

39 ic disease with slow progression, leading to multiorgan failure and death, decades after its first cl

40 s caused by large-scale trauma that leads to multiorgan failure and death, despite the stemming of bl

41 y mechanical circulatory support may prevent multiorgan failure and death.

42 esult in severe neurologic damage as well as multiorgan failure and death.

43 e can be associated with rapidly progressive multiorgan failure and devastating complications; howeve

44 However, these patients tended to be in multiorgan failure and encephalopathic.

45 ukopenia, and thrombocytopenia and developed multiorgan failure and hemorrhage.

46 Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill

47 coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, re

48 iced, survival was related to the absence of multiorgan failure and to higher platelet counts.

49 anada, the United States, and Europe who had multiorgan failure and were receiving mechanical ventila

50 ich is characterized by rashes, hypotension, multiorgan failure, and a high mortality rate.

51 R contributes to early death attributable to multiorgan failure, and an effective treatment has not b

52 ased susceptibility to secondary infections, multiorgan failure, and death.

53 slocates to the bloodstream, causing sepsis, multiorgan failure, and death.

54 d hyperoxia can lead to respiratory failure, multiorgan failure, and death.

55 eads to acute respiratory distress syndrome, multiorgan failure, and increased mortality.

56 aracterized by a protracted clinical course, multiorgan failure, and pancreatic necrosis.

57 e inflammatory processes that lead to shock, multiorgan failure, and purpura fulminans in meningococc

58 r Charlson comorbidity index, and those with multiorgan failure, and similar in males and females.

59 organ damage, such as acute chest syndrome, multiorgan failure, and sudden death.

60 of the recipient, who died 10 weeks later of multiorgan failure, and unusual findings at autopsy.

61 e control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansi

62 to uncontrolled inflammation, cachexia, and multiorgan failure as seen in the TGF-beta1 null mouse.

63 also contributes to the vascular damage and multiorgan failure associated with severe meningococcal

64 Despite multiorgan failure, bacteremia, and disseminated zygomyc

65 Three patients died of progressive multiorgan failure before any treatment was initiated.

66 rally well tolerated, with only 1 death from multiorgan failure before receiving stem cells.

67 verse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related.

68 CSA was greater in patients who experienced multiorgan failure by day 7 (-15.7%; 95% CI, -27.7% to 1

69 by inactivating JNK and p38, thus preventing multiorgan failure caused by exaggerated inflammatory re

70 aphylococcal superantigen-mediated shock and multiorgan failure characteristic of toxic shock.

71 illness and was more severe among those with multiorgan failure compared with single organ failure.

72 ctions associated with early onset shock and multiorgan failure define the streptococcal toxic shock

73 blood pressure </=75 mm Hg) with evidence of multiorgan failure (defined as serum creatinine level >3

74 ectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 eve

75 cipitating condition and the extent to which multiorgan failure ensues.

76 jury, chronic rejection, biliary sepsis, and multiorgan failure following retransplantation for prima

77 sis with rapidly progressive myocarditis and multiorgan failure from Ehrlichia chaffeensis in a previ

78 diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV-8.

79 infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other.

80 however, a prolonged response contributes to multiorgan failure, hypermetabolism, complications, and

81 y failure, respiratory infection, sepsis and multiorgan failure, ICU and hospital length of stay and

82 te myocardial infarction in two patients and multiorgan failure in five patients.

83 d lethal hemorrhagic fever with bleeding and multiorgan failure in human patients.

84 TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers.

85 % TBSA group; p<0.0001), 154 (16%) developed multiorgan failure (increasing from 6% [ten] in the 30-3

86 spitalization, the development of sepsis and multiorgan failure is a harbinger of poor outcome, but t

87 Septicemia with multiorgan failure is associated with chronic activation

88 risk for systemic sepsis and, in some cases, multiorgan failure leading to death.

89 emic inflammatory response that evolves into multiorgan failure, leading to death.

90 ntation as telomeropathy in adults, in which multiorgan failure may be prominent.

91 (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality.

92 Therefore, single-organ failure and/or multiorgan failure (MOF) are thought to contribute signi

93 e hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) in patients who have received c

94 In humans with sepsis, the onset of multiorgan failure (MOF), especially involving liver, lu

95 developed liver abnormalities and died from multiorgan failure on POD 22.

96 emed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all

97 ochondrial dysfunction can occur and lead to multiorgan failure or death.

98 with persistent liver dysfunction and either multiorgan failure or sepsis at a median of 40 days afte

99 mphohistiocytosis and has been attributed to multiorgan failure or the use of nephrotoxic drugs, but

100 t respiratory distress syndrome (OR = 1.55), multiorgan failure (OR= 1.49), and death (OR = 1.74).

101 We also evaluated whether evidence of multiorgan failure (requirement for supplemental oxygen,

102 e to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in ind

103 arrest, severe hemodynamic instability, and multiorgan failure results in poor outcome.

104 one from cerebral lymphoma and the other of multiorgan failure secondary to sepsis.

105 94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload.

106 825 mg/m2 of paclitaxel; one patient died of multiorgan failure that involved the lung, CNS, and kidn

107 rstitial lung disease and one as a result of multiorgan failure that occurred in the context of infec

108 increased risk of cardiovascular events and multiorgan failure, the fundamental mechanisms underlyin

109 systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly document the diagnosis and

110 at model of lipopolysaccharide (LPS)-induced multiorgan failure, we demonstrate that exposure to a lo

111 e of myocarditis, and one patient because of multiorgan failure with Guillain-Barre syndrome.